ABG
FATE icon

Ally Bridge Group’s Fate Therapeutics FATE Stock Holding History

Ally Bridge Group’s Portfolio FATE Stock Details FATE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-181,500
Closed -$4.5M – 40
2022
Q2 		$4.5M Hold
181,500
– – 4.1% 9
2022
Q1 		$7.04M Sell
181,500
-88,500
-33% -$3.43M 5.22% 7
2021
Q4 		$15.8M Hold
270,000
– – 5.52% 5
2021
Q3 		$16M Hold
270,000
– – 4.71% 7
2021
Q2 		$23.4M Hold
270,000
– – 5.82% 4
2021
Q1 		$22.3M Buy
270,000
+10,000
+4% +$958K 4.27% 6
2020
Q4 		$23.6M Buy
+260,000
New +$16.1M 4.05% 7

Other funds holding FATE

RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return
JJ
Johnson & Johnson New Brunswick, New Jersey $799M AUM 253.51% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
AG
Artal Group Luxembourg $931M AUM 41.63% 1-Year Est. Return

Ally Bridge Group's FATE Position: Q3 2022 in Review

Ally Bridge Group sold out of Fate Therapeutics (FATE) in Q3 2022, closing a stake of 181,500 shares — an estimated $4.5M sold.

Ally Bridge Group first reported a position in FATE in Q4 2020 and held it in 7 quarters. The position peaked at $23.6M in Q4 2020. 239 funds tracked by Wall St. Rank hold FATE as of Q3 2022.

  • Ally Bridge Group reported no remaining Fate Therapeutics position as of Q3 2022 after selling out during the quarter.
  • Ally Bridge Group sold 181,500 Fate Therapeutics shares in Q3 2022, an estimated $4.5M.
  • Ally Bridge Group first reported a position in Fate Therapeutics in Q4 2020 and held it in 7 quarters.
  • Ally Bridge Group's Fate Therapeutics position peaked at $23.6M in Q4 2020.
  • 239 funds tracked by Wall St. Rank held Fate Therapeutics as of Q3 2022.

Based on Ally Bridge Group's 13F filing for Q3 2022, filed 14 Nov 2022.